IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis

Tomoaki Mori, Takeshi Miyamoto, Hideyuki Yoshida, Mayoko Asakawa, Miyuri Kawasumi, Takashi Kobayashi, Hideo Morioka, Kazuhiro Chiba, Yoshiaki Toyama, Akihiko Yoshimura

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes irreversible joint damage and significant disability. However, the fundamental mechanisms underlying how inflammation and joint destruction in RA develop and are sustained chronically remain largely unknown. Here, we show that signal transducer and activator of transcription 3 (STAT3) is the key mediator of both chronic inflammation and joint destruction in RA. We found that inflammatory cytokines highly expressed in RA patients, such as IL-1β, tumor necrosis factor alpha and IL-6, activated STAT3 either directly or indirectly and in turn induced expression of IL-6 family cytokines, further activating STAT3 in murine osteoblastic and fibroblastic cells. STAT3 activation also induced expression of receptor activator of nuclear factor kappa B ligand (RANKL), a cytokine essential for osteoclastogenesis, and STAT3 deficiency or pharmacological inhibition promoted significant reduction in expression of both IL-6 family cytokines and RANKL in vitro. STAT3 inhibition was also effective in treating an RA model, collagen-induced arthritis, in vivo through significant reduction in expression of IL-6 family cytokines and RANKL, inhibiting both inflammation and joint destruction. Leukemia inhibitory factor expression and STAT3 activation by IL-1β were mainly promoted by IL-6 but still induced in IL-6-deficient cells. Thus, our data provide new insight into RA pathogenesis and provide evidence that inflammatory cytokines trigger a cytokine amplification loop via IL-6-STAT3 that promotes sustained inflammation and joint destruction.

Original languageEnglish
Pages (from-to)701-712
Number of pages12
JournalInternational Immunology
Volume23
Issue number11
DOIs
Publication statusPublished - 2011 Nov

Fingerprint

RANK Ligand
STAT3 Transcription Factor
Cytokine Receptors
Critical Pathways
Interleukin-1
Arthritis
Interleukin-6
Rheumatoid Arthritis
Joints
Cytokines
Inflammation
Interleukin-6 Receptors
Transcriptional Activation
Leukemia Inhibitory Factor
Experimental Arthritis
Osteogenesis
Chronic Disease
Tumor Necrosis Factor-alpha
Pharmacology

Keywords

  • Chronic inflammation
  • Collagen-induced arthritis
  • IL-6
  • Joint destruction
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology

Cite this

IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. / Mori, Tomoaki; Miyamoto, Takeshi; Yoshida, Hideyuki; Asakawa, Mayoko; Kawasumi, Miyuri; Kobayashi, Takashi; Morioka, Hideo; Chiba, Kazuhiro; Toyama, Yoshiaki; Yoshimura, Akihiko.

In: International Immunology, Vol. 23, No. 11, 11.2011, p. 701-712.

Research output: Contribution to journalArticle

Mori, T, Miyamoto, T, Yoshida, H, Asakawa, M, Kawasumi, M, Kobayashi, T, Morioka, H, Chiba, K, Toyama, Y & Yoshimura, A 2011, 'IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis', International Immunology, vol. 23, no. 11, pp. 701-712. https://doi.org/10.1093/intimm/dxr077
Mori, Tomoaki ; Miyamoto, Takeshi ; Yoshida, Hideyuki ; Asakawa, Mayoko ; Kawasumi, Miyuri ; Kobayashi, Takashi ; Morioka, Hideo ; Chiba, Kazuhiro ; Toyama, Yoshiaki ; Yoshimura, Akihiko. / IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. In: International Immunology. 2011 ; Vol. 23, No. 11. pp. 701-712.
@article{12e1609496a041489dea7ec7c037325d,
title = "IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis",
abstract = "Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes irreversible joint damage and significant disability. However, the fundamental mechanisms underlying how inflammation and joint destruction in RA develop and are sustained chronically remain largely unknown. Here, we show that signal transducer and activator of transcription 3 (STAT3) is the key mediator of both chronic inflammation and joint destruction in RA. We found that inflammatory cytokines highly expressed in RA patients, such as IL-1β, tumor necrosis factor alpha and IL-6, activated STAT3 either directly or indirectly and in turn induced expression of IL-6 family cytokines, further activating STAT3 in murine osteoblastic and fibroblastic cells. STAT3 activation also induced expression of receptor activator of nuclear factor kappa B ligand (RANKL), a cytokine essential for osteoclastogenesis, and STAT3 deficiency or pharmacological inhibition promoted significant reduction in expression of both IL-6 family cytokines and RANKL in vitro. STAT3 inhibition was also effective in treating an RA model, collagen-induced arthritis, in vivo through significant reduction in expression of IL-6 family cytokines and RANKL, inhibiting both inflammation and joint destruction. Leukemia inhibitory factor expression and STAT3 activation by IL-1β were mainly promoted by IL-6 but still induced in IL-6-deficient cells. Thus, our data provide new insight into RA pathogenesis and provide evidence that inflammatory cytokines trigger a cytokine amplification loop via IL-6-STAT3 that promotes sustained inflammation and joint destruction.",
keywords = "Chronic inflammation, Collagen-induced arthritis, IL-6, Joint destruction, Rheumatoid arthritis",
author = "Tomoaki Mori and Takeshi Miyamoto and Hideyuki Yoshida and Mayoko Asakawa and Miyuri Kawasumi and Takashi Kobayashi and Hideo Morioka and Kazuhiro Chiba and Yoshiaki Toyama and Akihiko Yoshimura",
year = "2011",
month = "11",
doi = "10.1093/intimm/dxr077",
language = "English",
volume = "23",
pages = "701--712",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis

AU - Mori, Tomoaki

AU - Miyamoto, Takeshi

AU - Yoshida, Hideyuki

AU - Asakawa, Mayoko

AU - Kawasumi, Miyuri

AU - Kobayashi, Takashi

AU - Morioka, Hideo

AU - Chiba, Kazuhiro

AU - Toyama, Yoshiaki

AU - Yoshimura, Akihiko

PY - 2011/11

Y1 - 2011/11

N2 - Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes irreversible joint damage and significant disability. However, the fundamental mechanisms underlying how inflammation and joint destruction in RA develop and are sustained chronically remain largely unknown. Here, we show that signal transducer and activator of transcription 3 (STAT3) is the key mediator of both chronic inflammation and joint destruction in RA. We found that inflammatory cytokines highly expressed in RA patients, such as IL-1β, tumor necrosis factor alpha and IL-6, activated STAT3 either directly or indirectly and in turn induced expression of IL-6 family cytokines, further activating STAT3 in murine osteoblastic and fibroblastic cells. STAT3 activation also induced expression of receptor activator of nuclear factor kappa B ligand (RANKL), a cytokine essential for osteoclastogenesis, and STAT3 deficiency or pharmacological inhibition promoted significant reduction in expression of both IL-6 family cytokines and RANKL in vitro. STAT3 inhibition was also effective in treating an RA model, collagen-induced arthritis, in vivo through significant reduction in expression of IL-6 family cytokines and RANKL, inhibiting both inflammation and joint destruction. Leukemia inhibitory factor expression and STAT3 activation by IL-1β were mainly promoted by IL-6 but still induced in IL-6-deficient cells. Thus, our data provide new insight into RA pathogenesis and provide evidence that inflammatory cytokines trigger a cytokine amplification loop via IL-6-STAT3 that promotes sustained inflammation and joint destruction.

AB - Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes irreversible joint damage and significant disability. However, the fundamental mechanisms underlying how inflammation and joint destruction in RA develop and are sustained chronically remain largely unknown. Here, we show that signal transducer and activator of transcription 3 (STAT3) is the key mediator of both chronic inflammation and joint destruction in RA. We found that inflammatory cytokines highly expressed in RA patients, such as IL-1β, tumor necrosis factor alpha and IL-6, activated STAT3 either directly or indirectly and in turn induced expression of IL-6 family cytokines, further activating STAT3 in murine osteoblastic and fibroblastic cells. STAT3 activation also induced expression of receptor activator of nuclear factor kappa B ligand (RANKL), a cytokine essential for osteoclastogenesis, and STAT3 deficiency or pharmacological inhibition promoted significant reduction in expression of both IL-6 family cytokines and RANKL in vitro. STAT3 inhibition was also effective in treating an RA model, collagen-induced arthritis, in vivo through significant reduction in expression of IL-6 family cytokines and RANKL, inhibiting both inflammation and joint destruction. Leukemia inhibitory factor expression and STAT3 activation by IL-1β were mainly promoted by IL-6 but still induced in IL-6-deficient cells. Thus, our data provide new insight into RA pathogenesis and provide evidence that inflammatory cytokines trigger a cytokine amplification loop via IL-6-STAT3 that promotes sustained inflammation and joint destruction.

KW - Chronic inflammation

KW - Collagen-induced arthritis

KW - IL-6

KW - Joint destruction

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=80055117937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055117937&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxr077

DO - 10.1093/intimm/dxr077

M3 - Article

VL - 23

SP - 701

EP - 712

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 11

ER -